Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q99616
UPID:
CCL13_HUMAN
Alternative names:
CK-beta-10; Monocyte chemoattractant protein 4; Monocyte chemotactic protein 4; NCC-1; Small-inducible cytokine A13
Alternative UPACC:
Q99616; O95689; Q6ICQ6
Background:
C-C motif chemokine 13, also known as Monocyte chemoattractant protein 4 (MCP-4), plays a pivotal role in immune responses. It functions as a chemotactic factor, attracting monocytes, lymphocytes, basophils, and eosinophils, signaling through CCR2B and CCR3 receptors. Its involvement is crucial in the accumulation of leukocytes during both allergic and non-allergic inflammation, and it has a significant role in atherosclerosis by recruiting monocytes into the arterial wall.
Therapeutic significance:
Understanding the role of C-C motif chemokine 13 could open doors to potential therapeutic strategies, especially in treating inflammatory conditions and atherosclerosis by modulating leukocyte recruitment.